In Q3, sales of Lantus were down 9.8% compared with the same period last year, at just under $1.4 billion. Sanofi announced this week plans to cut 20% of jobs in its US diabetes and cardiovascular ...

Levemir and Lantus are both long-acting injectable insulins that can be used for long-term management of diabetes. Insulin is a hormone that is naturally produced in the body by the pancreas. It ...

Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Sanofi said it will cut the price of Lantus by 78% and short-acting Apidra by 70% as of Jan. 1, 2024. The prices these companies set for insulin have increasingly been scrutinized by analysts, ...

Lantus may be available through a mail-order pharmacy. Using this type of service may help lower the drug’s cost and allow you to receive your medication without leaving home.

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect ...

Lantus is approved to treat type 2 diabetes in adults and certain children. (See “Uses of Basaglar vs. Lantus” below.) Drug forms: Basaglar and Lantus are available in prefilled pens.

Real-world study confirms Basaglar is as safe and effective in type 2 diabetes as Lantus, both formulations of insulin glargine, but the former was cheaper and had better adherence.

Sanofi defended Lantus's safety, saying that clinical trials found no cancer link--and pointed out that clinical trials do remain the "gold standard" of drug research.

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

The emergence of studies suggesting a possible link between the diabetes treatment Lantus and cancer is likely to create a long-term headache for drug giant Sanofi-Aventis SA, even as some medical ...